Enasidenib mesylate (1650550-25-6)pharmasino2025-07-10T08:59:27+00:00 Product InformationRelated ProductsAdditional InformationSupport & HelpAPIAnti-TumorEnasidenib MesylateEnasidenib mesylate (1650550-25-6)Product: Enasidenib Mesylate Description: CAS: 1650550-25-6; Enasidenib manufacturer; Enasidenib API; Anti-tumor Category: Anti-Tumor In-stock: In Stock Payment Method: T/T, L/C Shipping Method: AIR, Express Add To Inquiry ListProduct Information CAS No. 1650550-25-6 Specification CP, EP, As Required M.F. C20H21F6N7O4S M.W. 569.48 Assay 98% Shelf Life 2 Years Package 25kg/drum Highlight FARMASINO Enasidenib Mesylate FARMASINO Enasidenib manufacturer FARMASINO Enasidenib API Related Products 6-Bromomethyl-3,4-dihydro-2-methyl-quinazolin-4-one (112888-43-4) Gallery 6-Bromomethyl-3,4-dihydro-2-methyl-quinazolin-4-one (112888-43-4) Sodium Citrate (68-04-2) Gallery Sodium Citrate (68-04-2) Magnesium Stearate (557-04-0) Gallery Magnesium Stearate (557-04-0) Stearic Acid (57-11-4) Gallery Stearic Acid (57-11-4) Calcium Stearate (1592-23-0) Gallery Calcium Stearate (1592-23-0) Sodium Dihydrogen Phosphate (89140-32-9) Gallery Sodium Dihydrogen Phosphate (89140-32-9) Disodium Hydrogen Phosphate (7558-79-4) Gallery Disodium Hydrogen Phosphate (7558-79-4) Sodium Stearyl Fumarate (4070-80-8) Gallery Sodium Stearyl Fumarate (4070-80-8) Additional InformationApplication Enasidenib is a first-in-class oral selective inhibitor of mutant IDH2 enzymes (isocitrate dehydrogenase 2), for the treatment of adults with relapsed or refractory IDH2-mutated acute myeloid leukemia. Storage temp:Store at -20°C Solubility:DMSO : ≥ 100 mg/mL (175.60 mM) Form:Solid Color:White to off-white Support & HelpFirst name *Last name *Email *Product InterestsAPIPharmaceuticalsMedical DevicesSupplementsVeterinaryBudgetYour messageSend enquirySend enquiryThank you for your message. It has been sent.×There was an error trying to send your message. Please try again later.× *For more information about our products email us at: market@pharmasino.com Share This Story, Choose Your Platform! FacebookXLinkedInPinterest
